Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Precocious clonal hematopoiesis in Down syndrome is accompanied by immune dysregulation

Autor: Liggett, L. Alexander, Galbraith, Matthew D., Smith, Keith P., Sullivan, Kelly D., Granrath, Ross E., Enriquez-Estrada, Belinda, Kinning, Kohl T., Shaw, Jessica R., Rachubinski, Angela L., Espinosa, Joaquin M. ^*, DeGregori, James ^**

Publikováno v: In Blood Advances 13 April 2021 5(7):1791-1796

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity.

Autor: Araya P; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO 80045.; Departamento de Bioquímica Clínica, Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Universidad Nacional de Córdoba, Córdoba X5000, Argentina., Waugh KA; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO 80045., Sullivan KD; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO 80045.; Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045.; Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO 80045., Núñez NG; Departamento de Bioquímica Clínica, Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Universidad Nacional de Córdoba, Córdoba X5000, Argentina., Roselli E; Departamento de Bioquímica Clínica, Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Universidad Nacional de Córdoba, Córdoba X5000, Argentina., Smith KP; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO 80045., Granrath RE; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO 80045., Rachubinski AL; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO 80045.; Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO 80045., Enriquez Estrada B; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO 80045., Butcher ET; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO 80045., Minter R; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO 80045., Tuttle KD; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO 80045., Bruno TC; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213.; Tumor Microenvironment Center and Cancer Immunology and Immunotherapy Program, Hillman Cancer Center, Pittsburgh, PA 15213., Maccioni M; Departamento de Bioquímica Clínica, Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Universidad Nacional de Córdoba, Córdoba X5000, Argentina; mmaccioni@fcq.unc.edu.ar joaquin.espinosa@cuanschutz.edu., Espinosa JM; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO 80045; mmaccioni@fcq.unc.edu.ar joaquin.espinosa@cuanschutz.edu.; Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045.; Department of Molecular, Cellular and Developmental Biology, University of Colorado Boulder, Boulder CO 80309.

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2019 Nov 26; Vol. 116 (48), pp. 24231-24241. Date of Electronic Publication: 2019 Nov 07.